Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-08
2011-03-08
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S233000
Reexamination Certificate
active
07902238
ABSTRACT:
The invention relates to compounds of formulawhereinR1, R2, and R3are as defined herein and to a pharmaceutically suitable acid addition salts thereof for the treatment of CNS disorders.
REFERENCES:
patent: 2161938 (1939-06-01), Sonn
patent: 2457047 (1948-12-01), Kyrides
patent: 2731471 (1956-01-01), Synerholm et al.
patent: 2744909 (1956-05-01), Speeter
patent: 2744910 (1956-05-01), Speeter
patent: 2778836 (1957-01-01), Morren
patent: 2919274 (1959-12-01), Faust et al.
patent: 3161653 (1964-12-01), Fruhstorfer et al.
patent: 3354175 (1967-11-01), Fruhstorfer et al.
patent: 3377247 (1968-04-01), Eble
patent: 3577428 (1971-05-01), Suh et al.
patent: 3586695 (1971-06-01), Wysong et al.
patent: 3622579 (1971-11-01), Stahle et al.
patent: 3660423 (1972-05-01), Wysong et al.
patent: 3758476 (1973-09-01), Rippel et al.
patent: 3818035 (1974-06-01), Binon et al.
patent: 3818094 (1974-06-01), Stahle et al.
patent: 3992403 (1976-11-01), Roebke
patent: 4125620 (1978-11-01), Stahler et al.
patent: 4146647 (1979-03-01), Lafon
patent: 4311840 (1982-01-01), Condon
patent: 4323570 (1982-04-01), Stenzel et al.
patent: 4665095 (1987-05-01), Winn et al.
patent: 5610174 (1997-03-01), Craig et al.
patent: 5658938 (1997-08-01), Geerts et al.
patent: 6268389 (2001-07-01), Esser et al.
patent: 7098228 (2006-08-01), Binggeli et al.
patent: 2002/0019390 (2002-02-01), Wong et al.
patent: 2003/0181354 (2003-09-01), Abdulrazik
patent: 2003/0236274 (2003-12-01), Tasaka et al.
patent: 2 246 027 (2000-02-01), None
patent: 842 065 (1952-06-01), None
patent: 17 95 517 (1972-02-01), None
patent: 22 03 373 (1972-08-01), None
patent: 2 253 555 (1972-11-01), None
patent: 24 46 758 (1976-04-01), None
patent: 28 49 537 (1980-05-01), None
patent: 0 024 829 (1981-03-01), None
patent: 0 125 410 (1984-11-01), None
patent: 0 166 937 (1986-01-01), None
patent: 0 167 459 (1986-01-01), None
patent: 0 331 374 (1989-09-01), None
patent: 0 424 059 (1991-04-01), None
patent: 0 717 037 (1996-06-01), None
patent: 0 857 483 (1998-08-01), None
patent: 0 924 209 (1999-06-01), None
patent: 1 103 243 (2001-05-01), None
patent: 1 413 576 (2004-04-01), None
patent: 323 985 (1966-12-01), None
patent: 1 355 049 (1964-03-01), None
patent: 6 551 (1968-12-01), None
patent: 877306 (1961-09-01), None
patent: 1 016 514 (1996-01-01), None
patent: WO 96/22768 (1996-08-01), None
patent: WO 97/12874 (1997-04-01), None
patent: WO 98/12183 (1998-03-01), None
patent: WO 01/30762 (2001-05-01), None
patent: WO 01/81334 (2001-11-01), None
patent: WO 02/22801 (2002-03-01), None
patent: WO 02/40453 (2002-05-01), None
patent: WO 02/076950 (2002-10-01), None
patent: WO 03/092374 (2003-11-01), None
patent: WO 2004/014898 (2004-02-01), None
patent: 2005/016267 (2005-02-01), None
patent: WO 2006/119411 (2006-11-01), None
patent: WO 2007/024944 (2007-03-01), None
patent: 2008/074679 (2008-06-01), None
patent: 2008/092785 (2008-08-01), None
Deutch et al., (1999) Neurotransmitters. In Fundamental Neuroscien (2nded.) pp. 193-234, Academic Press.
Wong, et al., (2001) Nat. Rev. Neurosci. 2, pp. 343-351.
Carlsson et al. (2001) Annu. Rev. Pharmacol. Toxicol. 41, pp. 237-2.
Tuite et al. (2003) Expert Opin. Investig. Drugs 12, pp. 1335-1352.
Castellanos et al., (2002) Nat. Rev. Neurosci. 3, pp. 617-628.
Usdin, E. and Sandler. M.; Editors. Psychopharmacology Series, V Trace Amines and the Brain. [Proceedings of a Study Group at the 14th Annual Meeting of the American College of Neuropsychoparmacology, Juan, Puerto Rico] (1976) pp. 1-281.
Lindemann et al., (2005) Trends in Pharmacol. Sci. 26, pp. 274-281.
Branchek et al., (2003) Curr. Opin. Pharmacol. 3, pp. 90-97.
Premont et al. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, pp. 9474-94.
Mosseau et al., (1995) Prog. Brain Res. 106, pp. 285-291.
McCormack et al. (1986) J. Neurosci. 6, pp. 94-101.
Dyck, L.E. (1989) Life Sci. 44, pp. 1149-1156.
Parker et al., (1988) J. Pharmacol. Exp. Ther. 245, pp. 199-210.
Lindemann et al. (2005) Genomics 85, pp. 372-385.
Habib et al., Synthesis, 1984, pp. 825-827.
Trani et al., J. Heterocycl. Chem. 11, pp. 257-262 (1974).
Bunzow, J.R., et al., Molecular Pharmacology, vol. 60(6), pp. 1181-1188 (2001), XP008008060.
Holt, Andrew, J. of Psychiatry & Neuroscience, vol. 28(6), pp. 40 414 (2003), XP002438693.
Timmermans, P B M W M, et al., Life Sciences, vol. 28, No. 6, pp. 653-660 (1981), XP002442517.
Prisinzano, Thomas, et al., Bioorganic & Medicinal Chemistry Letters, vol. 14, No. 18, pp. 4697-4699 (2004), XP002442518.
Olmos, G., et al., European Journal of Pharmacology, vol. 262, No. ½ pp. 41-48 (1994), XP000567119.
McLennan, P.L., European Journal of Pharmacology, vol. 69, No. 4, 477-482 (1981), XP002442519.
Nathanson, J.A., Molecular Pharmacology, vol. 28., No. 3, pp. 25 268 (1985), XP009085722.
Akinori, et al., Bioorganic and Medicinal Chemistry, vol. 10, No. 1, 117-123 (2002), XP002442520.
Flippin et al., Tetrahedron Letters, vol. 34, pp. 3255-3258 (1993).
Liebigs, Ann. Chem. pp. 2061-2071 (1980).
Huh et al., Tetrahedron, vol. 58, pp. 9925-9932 (2002).
Huh et al., Tetrahedron, vol. 60, pp. 9857-9862 (2004).
Law et al., J. Med. Chem. vol. 41, pp. 2243-2251 (1998).
Debernardis et al., J. Med. Chem. vol. 29, pp. 1413-1417 (1986).
Mohammadpoor-Baltork, Bull. Korean Chem. Soc. vol. 24, p. 1354-1356 (2003).
Melloni et al., Eur. J. Med. Chem. vol. 26, pp. 207-213 (1991).
Abdollahi-Alibeik et al., Bioorg. Med. Chem. Lett. vol. 14, pp. 60 6082 (2004).
Amemiya, Synth. Commun. vol. 20, pp. 2483-2489 (1990).
Ohta, Chem. Pharm. Bull. vol. 35, pp. 1058-1069 (1987).
Olah, Synlett pp. 647-650 (1992).
Katz et al., Tetrahedron, vol. 45, pp. 1801-1814 (1989).
Wentland et al., J. Med. Chem. vol. 30, pp. 1482-1489 (1987).
Campos et al., Heterocycles, vol. 40, p. 841-849 (1995).
Ohta, Synthesis, pp. 78-81 (1990).
Mancuso et al., J. Org. Chem. vol. 43, pp. 2480-2482 (1978).
Mohammadpoor-Baltork, Synlett, pp. 2803-2805 (2004).
Cahiez et al., Synthesis, pp. 2138-2144 (1999).
Evans et al., Tetrahedron Lett. vol. 39, pp. 2937-2940 (1998).
Nakamura et al., J. Chem. Soc. Perkin Trans. 1, pp. 1061-1066 (2002.
Amemiya, et al., J. of Medicinal Chemistry, vol. 35(4), pp. 750-755 (1992), XP002151512.
Savola, J.M., et al., Drug Research, vol. 38(1), pp. 29-35 (1988), XP002033085.
Turner, et al., J. Org. Chem. (1991), 56, pp. 5739-5740.
Matsunaga, et al., Bioorganic & Medicinal Chemistry, p. 4314-43 (2004), XP002444990.
Matsunaga, et al., Tetrahedron: Asymmetry, Elsevier Science Publishers, vol. 15, No. 13, pp. 2021-2028 (2004), XP004520137.
Ojida, A., et al., Tetrahedron: Asymmetry, Elsevier Science Publishers vol. 15, No. 10, pp. 1555-1559 (2004), XP004508431.
Zhang, et al., Journal of Medicinal Chemistry, vol. 40, pp. 3014-302 (1997), XP002108693.
Ojida et al., Org. Lett. 2002, 4, pp. 3051-3054 (Supporting document attached).
Khimiya Geterotsiklicheskikh Soedinenii, 1988, pp. 77-79 (English lang abstract attached).
Reimann et al., Arch. Pharm. 1989, vol. 322, pp. 363-367.
Klapars, et al., J. Am. Chem. Soc. 2001, vol. 123, pp. 7727-7729.
Anderson, et al., Tetrahedron, 2002, vol. 58, pp. 8475-8481.
Touzeau et al., J. Med. Chem. 2003, vol. 46, pp. 1962-1979.
Debernardis et al., Conformationally Defined Adregernic Agents. Resolution, Absolute Configuration, and Pharmacological Characterizat of the Enantiomers of 2-(5,6-Dihydroxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline: A Potent Agonist at α-Adrenoceptors, J. Med. C (1987), 30:1011-1017.
Altenbach et al., Synthesis and Structure-Activity Studies onN-[5-(Imidazol-4-y1)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, Imidasole-Containing α1A-Adrenoceptor Agonist, J. Med. Chem. (2004) 3220-3235.
Carroll et al., In Vitro and In Vivo Characterization of Alpha-1A Selective Agonists and Their Utility for Stress Incontinence, Med. Chem Res. (2004), 13:134-148.
Jetter et al., Synthesis of 4-Substituted Imidazoles via Palladium-Catalyzed Cross-Coupling Reactions, Synthesis (1998), 829-831.
Bagley et al., Synthesis and α2-Adrenegeric Activities of Imidazole and Imidazolidine Analogues: In Vitro and In Vivo Selectivity, Medicinal Chemistry Res
Galley Guido
Groebke Zbinden Katrin
Norcross Roger
Stalder Henri
Hoffmann-La Roche Inc.
Johnston George W.
Prior Kimberly J.
Rocha-Tramaloni Patricia S.
Saeed Kamal A
LandOfFree
2-aminooxazolines as TAAR1 ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-aminooxazolines as TAAR1 ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-aminooxazolines as TAAR1 ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2670055